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T
here is a substantial amount of clin-
ical data showing the relationship
between diabetes and atherosclero-
sis and its clinical complications (1,2).
Cardiovascular disease (CVD) is more
common in people with diabetes than in
subjects without the disease, and when it
is present, it also has a more aggressive
course and a worse prognosis (3). The
bulk of epidemiological data has ﬁrmly
established that type 2 diabetes is associ-
ated with more than a twofold increased
risk for cardiovascular (CV) death. In the
case of subjects with type 1 diabetes, in
spite of the fact that the CVD rate is sig-
niﬁcantly lower compared with the pop-
ulation with type 2 diabetes, their relative
risk for coronary heart mortality is seven-
fold higher than in matched counterparts
without the disease (4). Despite all of
these data concerning the association of
diabetes and CVD, the exact mechanism
by which diabetes, and its alterations, is
linked to atherosclerosis remains incom-
pletely elucidated. This is especially true
in the case of hyperglycemia. The role of
nonglycemic factors that accompany the
vast majority of patients with type 2 di-
abetes, such as high blood pressure,
dyslipidemia, and hemorreological ab-
normalities,amongothers,ismuchbetter
understood and seems to be independent
ofglycemia.Inadditiontothis,therehave
beenstudiesdemonstratingthatinterven-
tionsaddressedtocontroltheseotherfac-
tors in patients with diabetes effectively
reduceCVrisk.Therealsohavebeendata
including the use of statins, aspirin, the
aggressive management of hypertension,
and the use of ACE inhibitors (5,6).
Therefore, the positive effects that the
control of other factors beyond hypergly-
cemia exert on CVD are, nowadays, un-
questionable. In contrast, to date, the
positive effect of intensive glucose man-
agement in comparison to nonintensive
glucose control on CVD outcomes is still
far from proven and seems unlikely to
changeinthenearfuture(7).Asanexam-
ple, the American Diabetes Association/
American Heart Association in their last
joint scientiﬁc statement on primary pre-
vention of CVD in people with diabetes
declared that, “No clinical trials of a gly-
cemic intervention have provided clear-
cut evidence that glucose lowering
reduces the risk of CVD in subjects with
diabetes”(8).Furthermore,oneofthelat-
est U.S. Food and Drug Administration
announcements on antidiabetic agents
clearly concluded that, “There is insufﬁ-
cient information available to determine
whether any oral antidiabetic medicine
reduces cardiovascular risk” in people af-
fected by diabetes.
AVAILABLE DATA
ASSESSING THE
CARDIOVASCULAR EFFECTS
OF GLUCOSE CONTROL
ONLY PROMISES FOR THE
REDUCTION OF RISK— Hyper-
tension and dyslipidemia, among other
risk factors for CVD, are common in sub-
jectswithdiabetes.Together,theycanex-
plain most, but not all, of the excess of
risk of CVD in patients affected by the
disease.Highbloodglucosehaslongbeen
considered a risk factor for developing
atherosclerosis, but data directly relating
this alteration to the development and
progressionofCVDareconﬂicting.Inthis
context, several glucose-lowering trials in
both type 1 and type 2 diabetes showing
signiﬁcant reductions in microvascular
complications have systematically failed
to achieve signiﬁcant reductions in mac-
rovascular events (5). Nevertheless, it
should also be mentioned that some sys-
tematic reviews and metanalysis per-
formed in type 1 and type 2 diabetes (in
thecaseoftype1diabetesincludingsome
studieswithfewsubjectsandnoneorvery
small number of CV events) have sug-
gested that attempts to improve glycemia
reduce the incidence of CVD (9,10).
Before going through “proper” trials
evaluating the effects of glycemic control
and CVD, the results of the diabetes Insu-
lin-Glucose Infusion in Acute Myocardial
Infarction (DIGAMI) trial require some
comments (11,12). The DIGAMI trial
demonstrated that a high-dose insulin in-
fusion followed by 3 months of intensive
subcutaneous insulin therapy was associ-
ated with a statistically signiﬁcant reduc-
tion in mortality after a 12-month
follow-upinpatientswithdiabetesandan
acute myocardial infarction (no signiﬁ-
cant differences in the primary end point
at 3 months of follow-up). In the study,
high doses of insulin infusion and high
blood glucose targets were used during
theacutephaseoftheprotocol.Moreover,
during the subcutaneous insulin treat-
mentperiodandconventionalclinicaltar-
gets of glucose control, there were no
differences in glucose values as expressed
by A1C. Thus, DIGAMI strictly could not
be considered a glucose-lowering trial
supporting the beneﬁcial effects of glu-
cose control. In addition to this, the re-
sults of the unsuccessful DIGAMI-2 trial
failed to ﬁnd signiﬁcant differences in
A1C using different strategies on glucose
management in type 2 diabetic subjects
andacutemyocardialinfarction,aswellas
in mortality and CV outcomes (13). In
conclusion, DIGAMI-2 did not provide
additional information conﬁrming or de-
nying the beneﬁcial effects of glucose
control.
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ered the ﬁrst glucose-lowering trial eval-
uatingtheCVeffectsofdifferentstrategies
aimed at glucose control in type 2 diabe-
tes (insulin addressed/not addressed to
intensive control, phenformin, tolbut-
amide, and placebo) (14,15). After 12.5
years of follow-up, there were no differ-
ences in CVD events between the inten-
sive control group with insulin, the
nonintensivecontrolinsulingroup,orthe
placebo. Phenformin and tolbutamide
were discontinued because of the devel-
opment of lactic acidosis and an excess of
CV mortality, respectively.
In the Veterans Affairs Cooperative
Study of Diabetes Mellitus (VACSDM),
153 subjects with type 2 diabetes were
followed up for a mean of 2.25 years
(16,17). This was a pilot feasibility trial in
which patients under intensive glucose
control (either with insulin or sulfonyl-
ureas) achieved a signiﬁcant reduction in
A1C(2.1%absolutereduction).Inspite
of this, there was a nonsigniﬁcant trend
toward an increase in CV events in the
group under intensive control.
The Kumamoto study was designed
to elucidate whether intensive glucose
control (multiple injections of insulin)
was associated with a decrease in the fre-
quency (primary prevention) or severity
(secondary prevention) of microvascular
complications in 110 patients with type 2
diabetes (18). After 8 years and a 2.2%
reduction in A1C, in the group receiving
intensive control, there were positive re-
sults in both primary and secondary pre-
vention of microvascular disease. After
evaluating the effect of intensive treat-
ment on CV events (cardiac, cerebrovas-
cular, and peripheral), this was not
signiﬁcant, and this negative result was
attributedtothesmallnumberofsubjects
included in the study by the authors.
Undoubtedly, the U.K. Prospective
Diabetes Study (UKPDS) is still the land-
mark study evaluating the effects of glu-
cose control on type 2 diabetes
complications (19). Including more than
3,800 subjects, the study demonstrated a
12% signiﬁcant reduction in a composite
of micro- and macrovascular type 2 dia-
betes–related end points. However, it
should be mentioned that UKPDS was
underpowered to speciﬁcally assess the
effect of improving glucose control on
CVD. There was a nonsigniﬁcant reduc-
tion (16%) in the risk of MI and a statis-
tically nonsigniﬁcant increase in the risk
of stroke (Table 1). The positive effects of
using metformin to improve glycemic
control is a large claim because it was sta-
tistically associated with beneﬁcial effects
preventing any diabetes-related end
point, diabetes-related mortality, and the
frequency of MI (20). However, these re-
sults derived from a substudy of UKPDS
werelimitedtooverweighttype2diabetic
subjects.
The use of pioglitazone in type 2 dia-
betes (secondary prevention) has been
evaluated in the PROspective pioglitA-
zone Clinical Trial In Macrovascular
Events (PROactive) (21). It was claimed
that the use of the drug was associated
with a positive and signiﬁcant reduction
inasecondarycompositeendpointofthe
study (death, stroke, and MI). Consider-
ing that the use of pioglitazone was asso-
ciated not only with a reduction in A1C,
but also triglycerides, the ratio of LDL to
HDL, and blood pressure, whether the
beneﬁcial effects of pioglitazone were due
to the improvement of glucose, to the
amelioration of the other CVD risk fac-
tors, or to both remains to be elucidated
(22).
The milestone study evaluating glu-
cose control improvement and diabetes
complicationsintype1diabetesistheDi-
abetes Control and Complications Trial
(DCCT) (23). As a result of this study,
intensive management of glycemia with
multiple insulin doses is the gold-
standard therapy in subjects with the
disease to reduce the burden of
microvascular complications (primary
and secondary prevention). Because of
the low rate of macrovascular events dur-
ing the follow-up, the study lacked
enough power to evaluate the effect of
glucose control on CVD (24) (Table 1).
The DCCT/Epidemiology of Diabetes In-
terventions and Complications (EDIC)
study followed up 1,341 initial partici-
pants evaluating CV events (17 years in
total after entry in the DCCT). There was
a 42% reduction for any CV event and a
57% reduction for CV death, MI, or
stroke in the group originally assigned to
intensive management (25). In spite of
the fact that the authors attributed this
positive ﬁnding to the DCCT period of
intensive glucose control, this piece of
data from the DCCT/EDIC study was de-
rived from an epidemiological and obser-
vational investigation. While exciting,
these results are far from deﬁnitive.
CONCLUSIONS — The lack of posi-
tive effects of glycemic control on CVD
complications in diabetes in the above-
mentioned trials that, up to now have as-
sessedthistopic,couldbeduetodifferent
factors: low number of subjects included,
low number of CV events, not lengthy
enough follow-up, low efﬁcacy of thera-
pies that have been used, the degree to
which glucose reduction might reduce
CVDeventshasnotbeenachieved,orjust
because the effect of glycemic control on
CVD is superﬂuous in comparison with
the effect of controlling other risk factors
indiabetes.Underthiscontext,theAction
to Control Cardiovascular Risk in Diabe-
tes (ACCORD) study, which was de-
signed to determine whether intensively
lowering blood glucose (below current
recommendations) would reduce the risk
of CV events or death from CVD, speciﬁ-
cally in people with type 2 diabetes who
were at a particularly high risk, recently
has shown that this strategy is associated
withanincreasedriskofdeath.Therefore,
Table 1—Effect of glycemic control on CVD in the UKPDS and DCCT studies
Intensive (rate/100
patient-years)
Conventional (rate/100
patient-years)
Risk
reduction (%) P
End points
UKPDS
Any diabetes related* 4.09 4.60 12 0.029
Myocardial infarction 1.47 1.74 16 0.052
Stroke 0.56 0.50 — 0.52
Peripheral vascular
disease
0.11 0.16 — 0.15
DCCT
Cardiac 0.06 0.29 78 0.065
Peripheral vascular
disease
0.43 0.55 22 0.16
Combined 0.49 0.84 42 0.082
From Refs. 19 and 24. *Combined microvascular and macrovascular events.
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may safely reduce CVD remains unclear.
Inconclusion,currently,therelation-
ship(ifthereisany)betweenglucosecon-
trolandCVDindiabetesisstillamatterof
controversy. The results of the effect of
intensive glucose control in comparison
with usual management of major CV
events are still inconclusive. In the mean-
time, an overall strategy toward risk man-
agement for our patients with type 1 and
type 2 diabetes should place appropriate
emphasis on blood pressure and lipid
control to reduce the leading complica-
tions of diabetes.
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